Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.48 |
| ▸ | GPR4 | P46093 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061663 | 0.95 | EPHX2 (0.54) | EPHX2GPR119HRH2HRH1ALDH1A1 | |
| SCHEMBL750227 | 0.82 | PRMT5 (0.42) | GPR119HRH2HRH1 | |
| SCHEMBL14453585 | 0.81 | KCNA5 (0.62) | EPHX2GPR4HRH2HRH1DRD3 | |
| SCHEMBL20423457 | 0.81 | DRD3 (0.55) | EPHX2GPR119GPR4HRH2HRH1 | |
| SCHEMBL19479118 | 0.81 | DRD3 (0.70) | HRH2HRH1DRD3ALDH1A1 | |
| SCHEMBL3080285 | 0.81 | MCHR1 (0.57) | EPHX2HRH2HRH1DRD3AR | |
| SCHEMBL23301374 | 0.80 | DRD3 (0.54) | EPHX2GPR119GPR4HRH2HRH1 | |
| SCHEMBL14453658 | 0.80 | DRD3 (0.54) | EPHX2GPR119GPR4HRH2HRH1 | |
| SCHEMBL6034847 | 0.80 | HRH2 (0.61) | EPHX2GPR119GPR4HRH2HRH1 | |
| SCHEMBL1730771 | 0.80 | HRH2 (0.58) | EPHX2GPR119GPR4HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| CN-102482280-A | [1,2,4] triazolo [4,3-b ] pyridazines as ligands for androgen receptors | ASTRAZENECA AB | 2012-05-30 | — | — | CN | disclosed |
| EP-2430024-A1 | [1,2,4]TRIAZOLO [4,3-B]PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | AstraZeneca AB (SE) | 2012-03-21 | — | — | EP | disclosed |
| CN-102388048-A | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer | ASTRAZENECA AB | 2012-03-21 | — | — | CN | disclosed |
| EP-2396333-A1 | TRIAZOLO [4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010131022-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | AR, NR5A1, KLK3 | EPHX2 1641/4885DDB1 3983/4885CRBN 733/4885 |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | EPHX2 2749/4885DDB1 4329/4885CRBN 1219/4885 |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | EPHX2 2573/4885DDB1 4202/4885CRBN 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.